BH4601 / Hanmi - LARVOL DELTA

Preclinical evaluation of BH4601, a novel tetravalent PD-L1 and B7H3 bispecific antibody-drug conjugate (ADC) with Topo1 inhibitor for the treatment of solid tumors (AACR 2026) - "Effective tumor control was demonstrated in multiple in vivo models, accompanied by significant T-cell activation. All animals remained well-tolerated at efficacious dose levels.By simultaneously engaging both PD-L1 and B7H3 pathways, BH4601 achieves enhanced tumor-specific distribution and efficient tumor cell internalization, potentially improving both efficacy and safety profiles compared to its parental ADCs."

ADC • Bispecific • IO biomarker • Preclinical • Oncology • Solid Tumor • CD276